General Information of Drug (ID: DM13OVF)

Drug Name
REMD 477 Drug Info
Synonyms Volagidemab
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 2 [1]
Type 2 diabetes 5A11 Phase 1/2 [2]
Type-2 diabetes 5A11 Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DM13OVF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Glucagon receptor (GCGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glucagon recombinant DMFLUTR Hypoglycemia 5A41 Approved [5]
Dasiglucagon DM74SVE Hypoglycemia 5A41 Approved [6]
Retatrutide DM8WU0Q Obesity 5B81 Phase 3 [7]
MK-8521 DMVNAYE Type-2 diabetes 5A11 Phase 2 [8]
LY2944876 DML6XWR Diabetic complication 5A2Y Phase 2 [9]
TT-401 DMRQ0SA Type-2 diabetes 5A11 Phase 2 [8]
LGD-6972 DMPL9KG Type-2 diabetes 5A11 Phase 2 [10]
PF-06291874 DMN94QM Type-2 diabetes 5A11 Phase 2 [11]
LY-2409021 DMZOIP4 Type-2 diabetes 5A11 Phase 2 [12]
Efinopegdutide DMAN2V2 Non-alcoholic steatohepatitis DB92.1 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Antagonist [4]

References

1 ClinicalTrials.gov (NCT03117998) Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
4 Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
5 Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7 Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
11 Clinical pipeline report, company report or official report of pfizer.
12 Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
13 Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.